INCY News and Press, Incyte Corporation From 10/19/22

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Has famed investor Cathie Wood lost her touch? The CEO Of Ark Invest and her team crafted exchange-traded funds (ETFs) that destroyed the broader market during the early days of the pandemic, but over the past year, it's been the other way around. Still, it's far too premature to give up on...

Knight Therapeutics ( OTCPK:KHTRF ) said its Brazilian affiliate United Medical filed a marketing authorization application to Brazil's health regulatory agency, ANVISA, for tafasitamab in combination with Bristol-Myers Squibb's ( BMY ) Revlimid (lenalidomid...

MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in com...

Incyte ( NASDAQ: INCY ), a biotech focused on oncology, announced Monday an agreement to acquire Villaris Therapeutics, a Cary, North Carolina-based drug developer focused on treatments for the skin condition vitiligo. Villaris, backed by healthcare-focused investment firm...

– Villaris shareholders to receive upfront payment of $70 million, with potential for up to $1.36 billion in additional milestone payments – Pre-clinical data for auremolimab demonstrate high potency, selectivity and efficacy in vitiligo – Acquisit...

Summary Biotech has pulled back sharply after a summer rebound, but the niche continues to outperform the S&P 500. One mid-sized biotech company is looking forward to better earnings ahead with a decent pipeline of oncology and dermatology products. With an attractive valu...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Incyte's ( NASDAQ: INCY ) drug Pemazyre to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. The decision to approve for the indication had been made on the basis of overall response rate and duration of response and a cont...

Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...